🧬 Organ-specific bioregulation

What actually decides this outcome, in order of size

This goal asks the reader to accept a specific model, and everything else follows from whether that model is true. Ranked by how much of the outcome each one owns:

1. Whether a short peptide can carry tissue-specific information at all. The claim is that a two-to-four residue sequence extracted from one organ acts on that same organ by restoring age-declined gene expression there. Supporting work exists at the level of gene expression and cell behavior: interleukin-2 expression in splenocytes Kazakova 2002, nucleolar organizer region activity in thymocytes Raikhlin 2004, proliferative and inflammatory pathways in a monocyte and macrophage line Avolio 2022. That is a mechanistic case built in cells, and reading it as one is the honest starting position.
2. Where the evidence comes from, which is unusually concentrated. The long-term human survival work comes from the originating program Khavinson 2003, much of the supporting literature is from the same group and originally in one language, and independent replication outside it is thin. That is a real limitation and it is a different objection from the mechanism being implausible. A systematic review of animal-derived nootropics is the nearest thing to an outside look at part of this category Alsulaimani 2021.
3. Which product class you are actually buying, because two very different things are sold under one name. The synthetic peptides Thymalin, Epitalon and Vilon are defined sequences. The cytamins, Timusamin, Cerebramin, Epiphamin, Tiramin, Prostalamin and Gepatamin, are oral organ concentrates: a peptide-and-nucleoprotein fraction rather than a single molecule, taken by a route that exposes it to gastric acid and brush-border peptidases first. They inherit the model and they do not inherit the pharmacokinetics, and the difference is not usually stated on the label.
4. Whether the target tissue has any read-out you can order. This is the part that decides whether a personal trial can mean anything. The thymus is the strongest case for the model because its decline is real and documented Liang 2022, and it is simultaneously the weakest case for measurement, because quantifying thymic output across the lifespan is an open problem in laboratory medicine rather than a test on a menu Middelkamp 2025.
5. Which claims are supported and which are extrapolated, because the boldest ones are on the pineal arm. Pineal peptide preparations have human work on the melatonin rhythm in older subjects Korkushko 2007 Trofimova 2017, which is a measurable endpoint. The telomerase claim is a different order of claim: cell-line work reporting telomere lengthening exists and so does its published correction Al-Dulaimi 2025 Al-Dulaimi 2025, and reading both is the only honest way to cite it.
6. Supply, which on this goal is not a footnote. These are unlicensed in most jurisdictions, there is no assay behind the vial, and the animal lifespan and tumor-incidence work that anchors the category was done with characterized material Anisimov 2003. What is in an unverified product is an open question before the mechanism is.

The order to run these in, and what has to be true first

Pick a tissue that has a read-out, baseline it, then run one thing for long enough to see a change in that read-out. The ordering principle is measurability, because on this goal a protocol you cannot check is a protocol you cannot learn from.

1. Decide first whether you want a tissue signal or a hormone. If a gland is failing and its hormone is low, the answer is replacement and a clinician. The bioregulator argument is upstream of that conversation rather than an alternative to it, which is the point Endocrine & reproductive makes and the reason Bonothyrk is not a thyroid prescription.
2. Baseline the read-out before the first dose, not after. Complete Blood Count (CBC) with Differential with differential for the thymic arm, IGF-1 (Insulin-like Growth Factor 1) and hs-CRP (High-Sensitivity C-Reactive Protein) as general context, and whichever organ marker matches the tissue: GGT (Gamma-Glutamyl Transferase) with the Comprehensive Metabolic Panel (CMP) for the hepatic arm, Cystatin C with eGFR for the renal one, PSA (Total + Free + % Free) for the prostatic one, TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) for the thyroid one.
3. Start with the thymus, because it is the arm where the underlying decline is best established. Thymus & immune holds Thymalin and Timusamin. The historical human work that used an immunological endpoint rather than a symptom is worth reading first Degtiarev 1988, and the involution it is aimed at is documented independently of this program Liang 2022.
4. The pineal arm second, because it is the one with a measurable circadian endpoint. Brain & pineal holds Epitalon, Cerebramin and Epiphamin. The melatonin rhythm is the read-out the human work used Korkushko 2007, and it is measurable by urinary 6-sulfatoxymelatonin without a clinic.
5. The clearance and barrier organs third, and only where a marker is already abnormal. Liver, kidney, gut & lung holds Gepatamin and Vilon. A liver enzyme that is already raised gives you something to watch; a normal one gives you nothing to detect.
6. The vascular and structural arm fourth. Vascular, cardiac & structural is where the tissues are measurable and the peptides are least studied, which is an unusual combination and the reason that page is written the way it is.
7. The endocrine and reproductive arm last, and never as a replacement for a hormone that is actually low. Endocrine & reproductive holds Tiramin and Prostalamin. If PSA (Total + Free + % Free) is rising or TSH (Thyroid-Stimulating Hormone) is abnormal, that is a clinical route rather than this one.

What gets bought for this that cannot move it

The thing that fails structurally on this goal is the oral route applied to a peptide argument. The cytamins are swallowed. A short peptide entering the stomach meets acid and then brush-border peptidases, and the fraction that reaches a target tissue intact is the unmeasured quantity the entire oral half of this category rests on. There are real answers available in principle, since very short sequences can survive and be transported where longer ones cannot, but the specific pharmacokinetic work for these specific preparations has not been published. That is an extrapolation, it is labeled as one here, and it is the single most useful experiment anybody could run on this goal.

The second failure is a read-out failure rather than a mechanism failure, and it is worth stating precisely. The model predicts a change in tissue-specific gene expression. Almost none of the target tissues has an assay a reader can order that would see such a change, and for the best-supported tissue the measurement problem is acknowledged in the literature Middelkamp 2025. So a personal trial on this goal usually generates a feeling and no data. That is not evidence the peptides do nothing; it is a reason to prefer the two arms that do have endpoints, which are the immunological one Degtiarev 1988 and the circadian one Korkushko 2007.

The telomerase claim is the one to be most careful with. Cell-line evidence of telomere lengthening exists and has been formally corrected in the record Al-Dulaimi 2025 Al-Dulaimi 2025. Lengthening a telomere in a dish is also, unavoidably, the capability a transformed cell needs, which is why Cellular senescence & senolytics treats this class of claim as double-edged rather than as a benefit.

If the goal underneath is different, so is the page. If the actual question is age-related immune decline with a measurable endpoint, Thymic function & adaptive immunity is the better route. If it is sleep timing, Circadian & melatonergic rhythm has instruments this goal does not. If it is a hormone that is low on a blood test, that is Testosterone & the male hormonal axis or Female hormonal balance and a prescriber. And none of these products is licensed as a medicine in most countries, which is a fact to plan around rather than a detail.

How you would know it was working, on a real read-out and a real timescale

This page makes two predictions, and both are about measurement rather than benefit. On the thymic arm, a Complete Blood Count (CBC) with Differential differential is too coarse to see what the model claims, so a null result there is not evidence against the model Middelkamp 2025; and on the pineal arm a circadian read-out is fine enough to see what the model claims, which makes it the only arm here where a personal trial can fail honestly.

• Complete Blood Count (CBC) with Differential with differential at baseline and 6 months on the thymic arm. Track the absolute lymphocyte count, and expect it to be uninformative: it counts cells, not new ones. Six months because the biology being addressed changes over years Liang 2022.
• Urinary 6-sulfatoxymelatonin, or a dim-light melatonin onset if one is available, at baseline and 3 months on the pineal arm. Three months because that is roughly the length of the human courses in the published work Trofimova 2017, and because a rhythm needs several weeks of stable conditions before it can be compared with itself.
• hs-CRP (High-Sensitivity C-Reactive Protein) and IGF-1 (Insulin-like Growth Factor 1) at baseline and 6 months, as general context rather than as targets. Neither is a bioregulator endpoint. They are here so that a change in either is noticed rather than attributed.
• The organ marker that matches the arm, at baseline and 3 months. GGT (Gamma-Glutamyl Transferase) with Comprehensive Metabolic Panel (CMP) for the hepatic peptides, Cystatin C with eGFR for the renal ones, PSA (Total + Free + % Free) for the prostatic ones, TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) for the thyroid one. An abnormal starting value is what makes this arm checkable at all.
• Sleep timing and infection episodes, written down rather than recalled, for twelve months. These are the two outcomes the human literature on this goal actually used Degtiarev 1988 Korkushko 2007, and they are free.

What will fool you. Courses on this goal are typically ten to twenty days and are then stopped, so any change is compared against a moving baseline. Subjective reports in this category are unusually strong, which is exactly what you would expect for an injectable, unlicensed, expensive product with a compelling story, and is the reason the endpoints above are all external. The animal lifespan work is in mice with a defined genotype and a defined tumor profile Anisimov 2003, and mouse lifespan is not a human read-out. And an unverified vial is an unknown dose of an unknown fraction, so a null personal result may be a product result rather than a mechanism result.

Sources read for these sections

• Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
• Degtiarev AA. Use of thymalin in stimulating an immune response in subjects inoculated with influenza vaccine. Voenno-Meditsinskii Zhurnal 1988 [Russian] · PMID 3206835
• Kazakova TB, Barabanova SV, Khavinson VKh, Glushikhina MS, Parkhomenko EP, Malinin VV, Korneva EA. In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes. Bulletin of Experimental Biology and Medicine 2002;133(6):614-616 · PMID 12447482
• Raikhlin NT. Expression of argyrophilic proteins in the nucleolar organizer regions of human thymocytes and thymic epitheliocytes under conditions of coculturing with vilon and epithalon peptides. Bulletin of Experimental Biology and Medicine 2004 · PMID 15455093
• Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003;4(4):193–202
• Al-Dulaimi S. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025 · PMID 40908429
• Al-Dulaimi S. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025 · PMID 41240216
• Korkushko OV. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Advances in Gerontology 2007 [Russian] · PMID 17969590
• Trofimova SV. Pineamin increased pineal melatonin synthesis in elderly people. Advances in Gerontology 2017 [Russian] · PMID 28849889
• Avolio F, et al. (co-authors include Khavinson VKh). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences 2022;23(7):3607 · PMID 35408963
• Liang Z. Age-related thymic involution: Mechanisms and functional impact. Aging Cell 2022 · PMID 35822239
• Middelkamp V. Measuring thymic output across the human lifespan: a critical challenge in laboratory medicine. GeroScience 2025 · PMID 39946072
• Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709